QLGN - Qualigen Therapeutics Inc
4.18
0.110 2.632%
Share volume: 15,298
Last Updated: Tue 21 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.75%
PREVIOUS CLOSE
CHG
CHG%
$4.07
0.11
0.03%
View ratios
| Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2024-07-02 | 2023-08-14 | 2023-11-14 | 2024-11-14 | 2024-07-02 | 2024-08-14 | 2024-11-14 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.651 M | 3.602 M | 2.778 M | 0.000 | 1.422 M | 1.741 M | 1.269 M | |
| Selling general and admin | 1.369 M | 2.427 M | 1.337 M | 0.000 | 1.057 M | 986.484 K | 1.145 M | |
| Research and development | 1.282 M | 1.175 M | 1.442 M | 0.000 | 364.385 K | 754.287 K | 123.429 K | |
| Total expenses | 2.651 M | 3.602 M | 2.778 M | 0.000 | 1.422 M | 1.741 M | 1.269 M | |
| 35.87% | -22.86% | -100.00% | 22.44% | -27.13% | ||||
| Operating income | -2.651 M | -3.602 M | -2.778 M | 0.000 | -1.422 M | -1.741 M | -1.269 M | |
| Ebit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Pretax income | -3.234 M | -3.533 M | -3.235 M | 0.000 | -2.031 M | -1.478 M | -1.796 M | |
| 9.27% | -8.44% | -100.00% | -27.24% | 21.55% | ||||
| Income tax | 1.393 K | 4.036 K | 0.000 | 0.000 | 1.786 K | -1.212 K | -2.198 K | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -4.107 M | -3.508 M | -3.695 M | 0.000 | -2.033 M | -1.577 M | -1.794 M | |
| 14.60% | -5.34% | 100.00% | 22.44% | -13.80% |